6th CMC-China Expo Showcases Full-Chain Transdermal Patch Solutions and Innovative Pharmaceutical Excipients

Hall B - B102 August 15

▷09:00-09:25 

Variability of CMC Studies for Peptide-Based Therapeutics During Clinical Development

Yuan Zifei, Gan & Lee Pharmaceuticals, Deputy General Manager, Chief Technology Officer

▷09:25-09:50 

Trends in the Development of Novel GLP-1 Receptor Agonists: Long-Acting Formulations and Multi-Target Approaches

Chen Xiaoxin, CEO of Zhongsheng Ruichuang

▷09:50-10:15 

Discovery and Clinical Translation of Innovative Dual-Target Agonists for GLP-1R/GIPR

Fang Yongliang, COO of Daoer Biology

▷10:15-10:40

iCVETide Peptide Novel Drug Discovery Platform: Technology and Practical Case Studies

Meng Guangpeng, Director of Innovative Drugs, Chengdu NovoShengtai

▷10:40-11:05 

Quality Control Strategies for Peptide Drugs

Fu Yuqing, Jianyuan Pharmaceutical, Senior Director of R&D

▷11:05-11:30 

Progress in the R&D of GLP-Based Drugs and Their Commercialization Prospects

Jing Shuqian, Chairman and CEO of Hongyun Huaning

▷11:30-12:00 

Roundtable Discussion: Expansion of Peptide Therapy and Overseas Opportunities

Fang Yongliang, COO of Daoer Bio

Chen Xiaoxin, CEO of Zhongsheng Ruichuang

Sun Handong, Deputy General Manager, Jiuyuan Gene

▷12:00-13:30 

Lunch

▷13:30-13:55 

GLP-1: Beyond Weight Loss, What Other Frontiers Are Being Contested?

Zuo Yajun, General Manager, Renhui Biopharma

▷13:55-14:20 

Case Study on Impurity Identification of Semaglutide and Tirzepatide

Liu Guozhu, Founder & Chairman of Changsha Chenchen Pharmaceutical

▷14:20-14:45 

The Path of Innovative R&D for Next-Generation Human-Derived Ultra-Long-Acting GLP-1 Drugs and Interpretation of Key Clinical Data

Jiang Fan, Yinuo Medicine, Board Secretary and Chief Financial Officer

▷14:45-15:10

Case Study: High-Throughput Screening and Peptide Microarray Screening Based on a Library of 2.4 Million Solid-Phase Peptide Molecules

Gao Jian, Chairman of Hetai Jianyu

▷15:10-15:35

Ipiutide: A Novel Broad-Spectrum Anti-Inflammatory Drug as an Alternative to Glucocorticoids

Xia Xianmin, Yicheng Biology, Chairman & General Manager

▷15:35-16:00

EMPHASES Peptide Synthesis Technology and Its Application in Pharmaceutical Peptide Synthesis

Zheng Qingquan, Founder & Chairman, Tongjun Pharmaceutical

▷16:00-16:25

Discovery of Innovative Cyclic Peptide Drugs: From Long-Acting Echinocandins to Oral PCSK9 Inhibitors

Yuan Chenguang, Xianggen Biotech, Co-founder & CSO

Scan the QR code to register now

Hall B - B103 August 15

Conference Chair: Xia Mingde, CEO of InnoLake

▷09:00-09:20

Lessons from the Delayed Approval of First-in-Class ADC Drugs Due to CMC Manufacturing Defects

Liu Cuihua, Senior Vice President, Bio-Thera Solutions

▷09:20-09:40 

Research, Clinical Development Progress, and Drugability Prospects of Small Peptides and Bispecific Conjugates

Shao Jun, Chief Technology Officer at Tongyi Medicine

▷09:40-10:00 

Yilian Bio’s TMALIN ADC Technology Platform: Enhancing Drug Efficacy and Identifying Targets in New Frontiers

Cai Jiaqiang, Yilian Bio, Co-founder & CSO

▷10:00-10:20 

ADC Drug Development from a MIDD Perspective

Su Xia, Senior Director of Clinical Pharmacology & Quantitative Pharmacology, Pharmaron

▷10:20-10:40 

The Future Is Here: End-to-End Innovative ADC Drug Discovery and Commercialization Development Model

Qin Gang, CEO of Qide Medicine

▷10:40-11:00 

The Specificity of Clinical Trial Design for Radiopharmaceuticals and Implementation Challenges

Liu Yan, Chief Medical Officer, Midu Bio

▷11:00-11:20 

Combination Innovation of ADCs

Xie Yuli, Founder & General Manager, Shanghai Weijing Biology

▷11:20-12:00 

Roundtable: How to Reduce Clinical Failure of XDCs Through Early-Stage Design?

1. Case Studies of Success and Failure in XDCs: From Early-Stage Design to Clinical Development

2. Analysis of Causes for Failure

3. What insights can be drawn from failed cases? How to avoid them

Xia Mingde, CEO of InnoLake (Moderator)

Liu Cuihua, Senior Vice President of Bio-Thera Solutions

Shao Jun, COO of Tongyi Medicine

Cai Jiaqiang, CSO, E-Link Biologics

Qin Gang, CEO of Qide Pharma
Xu Tao, Founder & CEO of Zhihe Bio

▷12:00-13:30 

Lunch

▷13:30-13:50 

Frontier Applications in Life Sciences: ADC Drug Development

Xu Yongyu, Revvity, Project Manager for Organoids and Biopharmaceuticals

▷13:50-14:10 

From a Financing and Investment Perspective on the Radiopharmaceutical Sector: Differentiated Innovative R&D Layout and Integrated Supply Chain Are Key
Tongrui Pharmaceuticals

▷14:10-14:30 

Exploring New Drug Modalities for Unmet Clinical Needs: Radiopharmaceutical Conjugates

Shan Bo, CEO of Borui Chuanghe

▷14:30-14:50 

NovuPharm’s Solutions for Innovative Radiopharmaceutical R&D and the Industrial Chain

Fang Peng, Chairman & Founder, Nuoyu Pharmaceutical

▷14:50-15:10 

Development of Nectin4-Targeted Radionuclide Conjugates

Xi Ning, Founder & CEO of Vancure

▷15:10-15:30 

Current Status of the Radiopharmaceutical Industry Development

Deng Qimin, General Manager, Chengdu Yunke Pharmaceutical Co., Ltd.

▷15:30-15:50 

Screening and Development of GPC3-Targeted Radiopharmaceuticals

Song Zheng, Vice President of Preclinical Development, Aboz Pharma

▷15:50-16:10 

Challenges and Strategies for Global Patent Layout of Radiopharmaceuticals

Tang Huadong, Partner at Merits & Tree Law Firm

Scan the QR code to register now

Hall B-B101 August 15-16

August 15

▷09:00-09:30

Henlius’s R&D Strategy (Pipeline Management and External Collaboration Needs)

▷09:30-10:00

The Highest Form of Warfare Is to Attack Strategy: How to Develop a Clinical Development Strategy

▷10:00-10:30

Yehui Pharma’s First-in-Class and Best-in-Class Innovation Strategies and Practices

▷10:30-11:00 

Innovent Biologics' R&D Strategy

▷11:00-11:30 

Progress in Claudin 18.2-Targeted ADC Drugs for Solid Tumors

▷11:30-12:00 

Roundtable: How Can Differentiated Biotech Companies Chart Their Path to Global Expansion?

▷12:00-13:30 

Lunch

▷13:30-14:00 

Progress in Assisted Reproductive Technology and Ophthalmology R&D Projects

▷14:00-14:30 

How to Resolve the Challenge of Balancing Safety and Efficacy in ADCs

▷14:30-15:00 

Progress in the R&D of Nectin-4-Targeted ADC Projects

▷15:00-15:30 

Use of bispecific strategies to reduce the toxicity of ADCs

▷15:30-16:00 

Selection and Development Practices of Nanobodies

▷16:00-16:30 

Differentiated Antibody Development Strategy

August 16

▷09:00-09:30 

Current Status and Potential Opportunities in Target Discovery for Antibody Drugs

▷09:30-10:00 

Antibody Differentiation: From Mechanistic Breakthroughs to Target Innovation

▷10:00-10:30 

Design and Development of Next-Generation Bispecific Antibodies

▷10:30-11:00 

Support of Antibody Drug Bioanalysis for Multi-Center Clinical Projects

▷11:00-11:30

Development of Bioanalytical and Immunogenicity Assay Methods for Antibody Therapeutics

▷11:30-12:00 

Roundtable: With Various Types of Antibodies Emerging Successively, What Is the Future Direction of Antibody Evolution?

▷12:00-13:30 

Lunch

▷13:30-14:00 

Analysis of Investment Trends in the Antibody Sector

▷14:00-14:30 

Antibody Characterization and Quality Control

▷14:30-15:00

Bioprocessing and Antibody Drug CMC

▷15:00-15:30 

Application of Novel Antibody Technologies in Radiopharmaceutical Drug Conjugates (RDCs)

▷15:30-16:00

Applications of AI in Antibody Drug Development

Scan the QR code to register now

Hall B-B102 August 16

▷09:00-09:20

mRNA Vaccines and mRNA Therapeutics

Hui Aimin, Founder of Huizhengqi Pharmaceutical

▷09:20-09:40 

Regulatory Challenges in the Development of Oligonucleotide Therapeutics

Yang Yongsheng, Senior Vice President and Dean of the Institute of Nucleic Acid Innovation at Haichang Biologics

▷09:40-10:00 

Early Development of Nucleic Acid Therapeutics

Guest itinerary being finalized

▷10:00-10:20 

Delivery and Clinical Progress of Small Nucleic Acid Interference Drugs

Yang Xianbin, CSO of Sirnaomics Greater China; General Manager of Sirnaomics China Headquarters in Suzhou

▷10:20-10:40 

Sources of Impurities in Oligonucleotide Drugs

Feng Bing, Senior Director of Oligonucleotide R&D at Zhongtai Biochemical

▷10:40-11:00 

Innovative Practices in Small Nucleic Acid Drugs

Su Xiaoye, Head of the Nucleic Acid Drug Research Institute, CSPC Pharmaceutical Group

▷11:00-11:20 

Nucleosidic phosphoramidites: an optimized approach in their synthesis, quality evaluation and impurities characterization

Beatrice Trucchi  Flamma S.p.A. - Italy R&D Project Manager

▷11:20-12:00 

BH-RACETM Novel Nucleic Acid Drug Platform

Hu Hanbin, Vice President of Hui Sheng Wu

▷12:00-13:30 

Lunch

▷13:30-13:50 

Delivery and Clinical Progress of Small Nucleic Acid Interference Drugs

Yuan Xudong, CEO of Aikang Pharmaceutical

▷13:50-14:10 

Novel siRNA Molecular Design for the Treatment of Liver and Lung Diseases

Huang Yi, Deputy Dean of Guowei Pharmaceutical Research Institute

▷14:10-14:30 

Quanhecheng Nucleic Acid Drug Delivery Platform (Proposed)

Song Yanmin, Quan Hecheng, Chairman

▷14:30-14:50 

Unlocking the Potential of Long-Acting Small Nucleic Acids: Case Studies in Chronic Disease Management (Draft)

Wan Jinqiao, General Manager of Xianyan Shengwu

▷14:50-15:10 

AI-Driven Efficient mRNA Vaccine Development

Caiyi Fei, VP & Co-founder of Chengshi Bio

▷15:10-15:30 

Dual-Targeting Aptamer Technology

Wang Xueqiang, Researcher, Hangzhou Institute of Medicine, Chinese Academy of Sciences

▷15:30-15:50 

Research Challenges and Case Studies in DMPK of Oligonucleotide Therapeutics

Chen Guiying, Director of the Chemical Drug Bioanalysis Department, Wuhan Hongren Biotechnology

Scan the QR code to register now

Hall B - B103 August 16

Planner & Moderator: Zhang Shuihua, Deputy General Manager, Xinyue Biotech

▷09:00-09:25 

Breakthroughs in Ferroptosis Research and the Emergence of New Therapies

Xu Jun, Professor at Sun Yat-sen University, Founder and CSO of Sino-Singapore Biopharma

▷09:25-09:50 

Screening and Case Studies of Smart DEL (Combining DEL and AI)

Jin Feng, Deputy General Manager of Xinyue Biotech

▷09:50-10:15 

Explore New DEL Modality Beyond Binding Assay

Huang Yiran, Deputy Director of the New Drug Screening Center, Guangdong Provincial Innovation Center for Small Molecule New Drugs

▷10:15-10:40 

Boehringer Ingelheim’s Strategic Direction for External Collaboration in Frontier Biopharmaceutical Innovation

Han Qifeng, Deputy Director, Global Business Development and Licensing, Boehringer Ingelheim

▷10:40-11:05

Trends in New Technologies for Drug Discovery: Their Respective Advantages and Characteristics

Zhang Qiang, Professor at Zhejiang University; Chief Scientist at Shandong Boguan

▷11:05-11:30

Key Points in Project Initiation Assessment and Early Drug Discovery for Innovative Drugs

Zhou Houjiang, Professor at Zhejiang University; Chief Scientist at Shandong Boguan

▷11:30-12:15 

Roundtable Discussion: What Are the Primary Objectives in the Early Stages of Drug Development? What Constitutes Successful Early-Stage Drug Development?

He Yun, Director of the Bairui Innovation Center at Shenzhen Bay Laboratory
Hu Wei, Senior Director, Innovation Cooperation Center, Eli Lilly China

Bian Feng, Executive Director of the China Integrated Science Team, Global Drug R&D, BMS

Fang Jianwu, Vice President, Darui Biotech

Wu Hongzhong, Vice President of Business Development, Molecule Mind

▷12:15-13:30 

Lunch

Development of Targeted Protein Degradation Drugs

Planner & Host: Zeng Li, CEO of Hejing Pharma

▷13:30-13:55

Everything Can Be Degraded: A Discussion on the Development Strategy of Targeted Protein Degradation Drugs

Feng Yan, CEO of Lingtai Bio

▷13:55-14:20 

Construction of the GlueTacs® Protein Degradation Platform and Drug Development in the Fields of Oncology and Immunological Diseases

Yang Xiaobao, Founder, Chairman and CEO of Biaoxin Bio

▷14:20-14:45 

Progress in Bi-XDC Technology and Clinical Research

Wang Guitao, Deputy General Manager and Dean of the Research Institute at Tongyi Medicine

▷14:45-15:10

Chaperone-Mediated Protein Degradation Technology Platform

Ying Wenwen, Founder and CEO of Rannuo Biotech

▷15:10-15:35 

PROTAC Drug Development Based on Tumor-Specific E3 Ligases

Zhang Jiyue, Co-founder and CEO of Aorui Pharmaceutical

▷15:35-16:15 

Roundtable Discussion: What Are the Technological Development Trends and Challenges in Protein Degradation Technology?

Zeng Li, CEO of Hejing Medicine (Moderator)

Feng Yan, CEO of Lingtai Bio

Yang Xiaobao, Founder, Chairman, and CEO of Biaoxin Biotech

Ying Wenwen, Founder and CEO of Rannuo Biotech

Yimin Hu, Co-founder and CSO of Chimergen Tx

Scan the QR code to register now

Hall B - B104+105 August 15-16

Forum 1: Agriculture, Food, and Energy

▷09:30-10:00

Leader in Synthetic Biology Manufacturing of Bulk Non-Food Alkyd Resins

Yang Shihui, Professor at Hubei University, Deputy Director of the State Key Laboratory of Biocatalysis and Enzyme Engineering (co-established by the province and the ministry), and Founder of Wuhan Ruijiakang Biotechnology Co., Ltd.

▷10:00-10:30

At the Right Time: Applications and Scientific Evidence of Ergothioneine Across Various Fields

He Rujun, Co-Founding Partner and Vice President of Raw Materials at Jin San Biology

▷10:30-11:00

Applications of Artificial Intelligence in the Field of Sugar Substitutes

Gao Hang, CFA, Managing Director at Fosun RZ Capital

▷11:00-11:30

Synthetic Biology Component: NMN (Proposed)

Zhang Qi, Founder and CSO of Bontac Bioengineering

▷11:30-12:00

Biosynthesis of Microalgae-Derived L-Astaxanthin

Qu Yujiao, Head of Protoga Labs, Shenzhen Peacock Talent

▷11:30-12:00

Topic to be determined

Fang Xu, Founder and Chief Scientist of Shandong Henglu Biotechnology Co., Ltd.

Forum 2: Medical Aesthetics, Pharmaceuticals, and General Health

▷13:30-14:00

Innovation and Application of Cosmetic Ingredients Based on Plant Synthetic Biology

Wang Yuliang, Deputy Director of the Plant Biotechnology Research Center at Shanghai Jiao Tong University and Master’s Thesis Supervisor at the School of Agriculture and Biology, Shanghai Jiao Tong University

▷14:00-14:30

Innovative R&D and Clinical Evidence of Probiotics and Prebiotics in Specialized Nutrition

Zeng Zhe, Senior Scientist at Danone Global Research & Development Center (Utrecht, Netherlands) & Head of Probiotics (Scientific Affairs), Asia-Pacific Region

▷14:30-15:00

Applications of Extracellular Matrix Protein Combinations (ECMP) in the Beauty and Skincare Industry and Solutions for Problematic Skin

Zhao Jun, Director of the Anhui Provincial Joint Key Laboratory of Synthetic Biological Proteins

▷15:00-15:30

Microbial Biosynthesis of Natural Products from Rare Medicinal Plants

Liu Xiaonan, Associate Research Fellow, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences

▷15:30-16:00

(Proposed) "Negative-Carbon" Industrial Development of the High-Value Product "Sakuranetin"

Shao Hui, Founder of Guangyue Bio

▷16:00-17:00

Innovative Breakthroughs of Synthetic Biology in the Aesthetic Medicine Field: From Genetic Customization to Beauty Regeneration
Zhang Li, Founder of Yuanyi Bio

▷16:00-17:00

Roundtable Discussion: Regulatory Challenges Facing Synthetic Biology

Forum 3: Bio-Manufacturing

▷09:30-10:00

Research on Artificial Intelligence in the Protein Field (Proposed)

Hong Liang, Professor at the School of Natural Sciences, School of Physics and Astronomy, and School of Pharmacy, Shanghai Jiao Tong University

▷10:00-10:30

Research on AI-Based Prediction of Protein-Protein Interactions and Its Applications

Chang Shan, Director of the Institute of Bioinformatics and Pharmaceutical Engineering, Jiangsu University of Technology

▷10:30-11:00

DNA Editing

Xinsu Technology

▷11:00-11:30

Generative AI Large Model-Driven Protein Research and Development and Production

Tang Jian, Founder and CEO of BioMap

▷11:30-12:00

Challenges from the Laboratory to Commercialization

Forum 4: Technologies and Tools

▷13:30-14:00

Synthetic Biology Industrialization Platform

Guo Hongming, Chairman of Jiangsu Huili Biotechnology

▷14:00-14:30

The New Engine of Synthetic Biology: AI Large Models for Enzyme Engineering, Discovery, and Industrialization Case Studies (Proposed)

Lu Xingyu, CMO of Tianwu Technology

▷14:30-15:00

Enzyme Evolution Technology Reshapes the Ecosystem of API Intermediate Synthesis

Liu Xiang, CEO of Meifutai Bio

▷15:00-15:30

Application of Enzyme Engineering and Immobilization Technologies in the Preparation of Intermediates and Active Pharmaceutical Ingredients

Zhu Wei, General Manager of Shangke Biotechnology

▷15:30-16:00

Development of Innovative Live Biotherapeutic Products Based on Bacteroides fragilis

Li Ping, Deputy General Manager of Zhiyi Biopharma; Deputy Director of the Guangdong Provincial Engineering Technology Research Center for Live Biotherapeutic Products

▷16:00-17:00

Synbio Suzhou Outstanding Synthetic Biology Enterprise Award Ceremony

Forum 5: Pitch Session for High-Quality Projects

▷09:30-9:50

Efficient Production of Salidroside via Microbial Fermentation

▷9:50-10:00

HMO Project

▷10:00-10:15

Synergistic Enhancement of Plant Polyphenols and the Development and Industrial Value of Purple-Phenolic Lettuce as a Dual-Purpose Food and Medicine

▷10:15-10:30

Plant Synthetic Biology: Green and Sustainable Production of Biopharmaceuticals

▷10:30-10:45

Purisen Synthetic Microbiology Platform

▷10:45-11:00

AI-Driven Decision-Making Product for Label Data Based on Nanorobotics-Enabled Ultra-Limit Detection Technology

▷11:00-11:15

Synthetic Biology Breeding – Aromatic Raw Materials Project

▷11:15-11:30

Industrialization Project of Bio-based Long-Chain Dicarboxylic Acids and Long-Chain Nylons

▷11:30-11:45

Bio-based Green New Materials Empower Sustainable Development

Forum 5: Commercialization and Post-Processing

▷09:30-10:00

Biomanufacturing Process Control and Optimization (Proposed)
Fang Baishan, Professor at Xiamen University

▷10:00-10:30

Construction of Cell Factories (Proposed)
Shi Shuobo, Professor at Beijing University of Chemical Technology

▷10:30-11:00

Downstream Processing of Synthetic Biology Products

▷11:00-11:30

Isolation and Purification of Collagen
Zhang Qingwu, Chief Engineer of Beijing Rixin Yuanwang Technology Development Co., Ltd., Professor, and Senior Engineer at the Researcher Level

▷11:30-12:00

Application of Novel Separation Technologies

Scan the QR code to register now

Hall C - C102 August 15

▷09:00-09:25

How to Navigate the Complex Biopharmaceutical Industry Landscape (Draft)

Wang Xingli, Fosun Pharma, Executive President & Co-CEO of Innovative Pharmaceutical Business Unit

▷09:25-09:50

Navigating Market Cycles: What Opportunities Remain for Chinese Biotech Companies Under Pressure?

Cai Xuejun, Former Global Vice President of R&D at BMS

▷09:50-10:15

The Inescapable Path to Commercialization: How Should Biotech Companies Approach It? (Draft)

Liu Qian, Vice President, AstraZeneca China

▷10:15-10:40

MNC Perspective: The Shift in the Role of Multinational Corporations in the Chinese Market

▷10:40-11:05

Release of the 2024 Series of Rankings on the Comprehensive Strength of Chinese Pharmaceutical Enterprises

Yang Jianyun, Deputy General Manager, Yaorong Cloud

▷11:05-11:30

Analysis of Investment Opportunities in China's Biopharmaceutical Industry

Mao Hua, Sullivan, Partner and Managing Director, Greater China

▷11:30-12:00

Roundtable: What Are the Future Breakthrough Points for Chinese Biotech Companies?

1. Being acquired by an MNC: Are you prepared?

2. Included in Volume-Based Procurement: Is the Growth Potential of Innovative Drugs Really That Promising?

3. Exit via acquisition by major domestic pharmaceutical companies?

4. Seizing the Opportunity to Transition from Biotech to Biopharma?

5. Fostering Innovation Through Imitation? How?

6. Balancing CRO services to generate cash flow? Is the competition too fierce to sustain?

Deng Yongqi | Kaifu Pharma, CEO (Moderator)

Wang Xingli | Fosun Pharma, Executive President & Co-CEO of the Innovative Drugs Business Unit

Jin Fang | Chief Scientist, Joincare

Liu Qian | Vice President, AstraZeneca China

▷12:00-13:30

Lunch

Rational Development Directions for New Drugs in China

Planner & Host: Dang Qun, President, Zhenshi Bio

▷13:30-13:55

Innovative Drugs: FIC or BIC? Addressing Unmet Clinical Needs Is Key!

Dang Qun, President, True Biologics

▷13:55-14:20

Development Progress of Abivax's FGFR Inhibitor

Chen Zhui, Co-founder and CSO of HeYu Pharma

▷14:20-14:45

Preclinical Efficacy Evaluation of Cell Therapy Products in Animal Models

Cao Baohong, Vice President of the Pharmacology Department at Medicilon

▷14:45-15:10

Development of YAP/TEAD Inhibitors

Zhu Jidong, CEO of Yituo Medicine

▷15:10-15:35

A Brief Overview of the Past and Present of “Prodrugs”: Changcheng Pharma’s Prodrug R&D

Song Qinhui, CMO of Changcheng Medicine

▷15:35-16:00

Research and Development of Innovative Drugs for the Functional Cure of Chronic Hepatitis B

Zhang Chi, Deputy General Manager, Xi'an Xintong Pharmaceutical

▷16:00-16:25

Delivery of Excellence - Delivery-Guided Drug Innovation

Shen Wang, Founder, Chairman & CEO of Weimou Bio

Scan the QR code to register now

Hall C - C101 August 15

▷09:00-09:10

Address by Li Ning, Vice Chairman of Junshi Biosciences

▷09:05-09:20

Overview of Emerging Medical Products
Du Xin, Co-founder & CEO of Eglin Pharma

▷09:20-09:45

Development Trends and Regulatory Challenges of Emerging Medical Products
Lu Jinhua, CSO, Stardust Bio

▷09:45-10:10

Key Considerations for Clinical Trials of CGT Products
Li Changqing, Egrin Pharma, Co-founder & CMO

▷10:10-10:35

Clinical Pharmacology Considerations for CGT Products
Yang Jin, Professor, China Pharmaceutical University

▷10:35-11:00

cGMP Compliance Considerations for CGT Products
Sun Zhigang, Senior Vice President, Luye Pharma Group

▷11:00-12:00

Group Discussion: The Internationalization of Emerging Medical Products
Du Tao, Wang Yaping, Hu Yuzhi, Bi Lücun, Zhang Mingdong, Wang Youmin

▷12:00-13:30 Lunch

▷13:30-14:00

Development and Regulatory Considerations for Small Nucleic Acid Drugs
Yang Yongsheng, Haichang Biotechnology, Senior Vice President & Dean of the Institute for Nucleic Acid Innovation

▷14:00-14:30

FDA Regulation of Oncolytic Virus Products
Jing Zhang, CMO at Jieke Biology

▷14:30-15:00

Controversy Surrounding the FDA Review and Approval of the First DMD Gene Therapy: A Case Study
Wang Yaning, Founder & CEO of Ruiningkang Biopharmaceuticals

▷15:00-15:30

Regulatory Landscape of the U.S. Food and Drug Administration for the Use of Artificial Intelligence and Machine Learning in Drug Development
Han Xiaomei, Founder & CEO of E7 CAPITAL

▷15:30-16:00

Regulatory Strategies for AI/ML-Innovative Medical Devices
Hu Yunfu, Chief Medical Officer, Genetron Health

▷16:00-16:45

Panel Discussion: Further Deepening the Regulation of Emerging Medical Products
Chen Shaoyu, Men Yuxin, He Ruyi, Zhao Xiaobin, Wang Yuping, Gao Guang, Dou Jinhui, Wen Hong

Scan the QR code to register now

Hall C - C103, August 15-16

Conference Chair: Yang Xiugao, CSPC Pharmaceutical Group, Senior Medical Director

Zheng Hang, Professor at Chongqing Medical University

August 15

▷09:00-09:25

Clinical Development Strategies for Central Nervous System Drugs from a Clinical Perspective: Case Studies and Insights

Shen Huaqiong, Neuscent Medicine, Founder & CEO

▷09:25-09:50

Indication Selection Strategy for Clinical Development of New Drugs

Yonghong Zhu, CMO, Biocytogen

▷09:50-10:15

Case Analysis of Failed Pivotal Clinical Trials

Chen Xia, Tigermed, Senior Vice President & Chief Medical Officer

▷10:15-10:40

Analysis of Clinical Studies on Dose Optimization and Safety Management Measures for Antibody-Drug Conjugates (ADCs)

Yang Xiugao, Senior Medical Director, CSPC Pharmaceutical Group

▷10:40-11:05

Challenges and Prospects of ADC Development from a Clinical Perspective

Shi Yan, Chief Medical Officer, Qide Pharma

▷11:05-11:30

How Difficult Is It for Chinese-Made Products to Go Global?

Du Yiming, Senior Vice President, Shanghai Haihe Pharmaceutical

▷11:30-12:10

Roundtable: What Are the Weaknesses in Registration and Clinical Globalization Operational Techniques for China’s Innovative Drugs?

Li Yikai, Vice President

Liu Yanwei, Vice President, Takeda China; Head of Regulatory Affairs, Takeda Greater China

▷12:10-13:30

Lunch

▷13:30-13:55

Clinical Development Strategies for Innovative Oncology Drugs from a Clinical Perspective: Case Studies

Sui Hong, Medical Director, Zhejiang Yingkang Biopharmaceutical Co., Ltd.

▷13:55-14:20

Drug Development for Neurodegenerative Diseases: Looking to the Future from the Past

Chen Baizhou, CEO of Jialisheng Biotech

▷14:20-14:45

TBD

Yan Huang, Head of Medicine, Suzhou Sinovent

▷14:45-15:10

Clinical Development Strategy and Key Points for Semaglutide

Meng Jietian, Chief Medical Officer, Anhui Wanbang

▷15:10-15:35

Case Studies on AI-Powered Medical Translation and Automated Clinical Trial Protocol Writing

Guest Itinerary: To Be Confirmed

August 16

Innovative Design and High-Quality Development of Clinical Trials

▷09:00-09:30

New Quality Productive Forces Drive High-Quality Development of Clinical Trials

Zhou Huan

Young Chair, Committee on Clinical Drug Trials, Chinese Pharmacological Society

▷09:30-09:50

The Current Status and Future of Digitalization in Clinical Trials

Zheng Hang, Professor, School of Pharmacy, Chongqing Medical University

▷09:50-10:10

Early-Stage Clinical Studies and Case Sharing of Gene Therapy Products

Lu Hua, Senior Vice President, Tianze Yuntai

▷10:10-10:30

Innovative Design and Implementation of Clinical Trials

Tang Zaixiang, Professor of Biostatistics at Soochow University

▷10:30-10:50

Selection of Endpoints in Clinical Trials of Antineoplastic Drugs

Ren Yizhong, Senior Director of Medical Affairs, Baoyuan Pharmaceuticals

▷10:50-11:10

Customized Strategies for International Multicenter Clinical Trials of Innovative Drugs

Guest Itinerary Pending Confirmation

▷11:10-11:30

Opportunities and Challenges for Chinese Clinical Trials Going Global

Deng Xiaoyu, Founder/General Manager, Xiyi Medicine

▷11:30-11:50

Applications of Real-World Data in Clinical Research

Hu Hao, General Manager, Yishu Kangcheng

▷11:50-13:30

Lunch

▷13:30-14:00

The Significance of Clinical Study Design and Quality from the Perspective of Regulatory Science

Yan Hou, Researcher, Department of Biostatistics, Peking University

▷14:00-14:30

New Developments in the Regulation of Drug-Device Combination Products in China

Xu Wei, Former Deputy Director of the Center for Medical Device Technical Evaluation, National Medical Products Administration

▷14:30-15:00

Digital Empowerment for Regulatory Decision-Making: An Intelligent Service Platform for Modern Drug Regulation

Wang Weiyu, Co-founder, Beijing Lingxun Pharmaceutical Technology Co., Ltd.

▷15:00-15:20

Integration and Implementation of DCT in Clinical Practice: A Patient-Centric Perspective

Xia Suqin, General Manager, Chuangda Pharmaceutical

▷15:20-15:40

The Interplay Between “Quality” and “Quantity” in Clinical Trials: Does Greater Effort and More Procedures Guarantee Better Quality?

Zhang Miao, Founder, Nanjing Maps Pharmaceutical Technology Co., Ltd.

▷15:40-16:00

Compensation for Damages and Risk Management of Adverse Events in Clinical Trials

Liu Yaqing, Deputy General Manager, Shanghai Pudong Wuxin Insurance Brokerage Co., Ltd.

Scan the QR code to register now

Hall C-C101, August 16

Planner & Moderator: Zhang Ligang, General Manager of China Business Region, WuXi AppTec

▷09:00-09:20

(Proposed) Progress in the Development of CD47/PD-1 Bispecific Antibodies

Li Qixiang, Co-founder & President and Chief Scientific Officer at Hansi Bio

▷09:20-09:40

Immunotherapy: Bispecific Antibodies vs. Cell Therapy

Gu Jinming, Former Head of R&D, China Region, Legend Biotech

▷09:40-10:00

ImmunoCytokine: The New Era of Cancer Immunotherapy

Yin Liusong, Shenghe Biotech, CEO & CSO

▷10:00-10:20

Regulatory T Cells  and Personalized Immunotherapy

Li Bin, Distinguished Professor, Shanghai Jiao Tong University; Deputy Director of Scientific Research, Shanghai Institute of Immunology

▷10:20-10:40

Humanized Mouse Models Accelerate the Development of Immunotherapy Drugs

Guest Itinerary: To Be Confirmed

▷10:40-11:00

Novel Bispecific Antibody Macrophage Engager for Cancer Immunotherapy (Proposed)

Lu Hongtao, Co-founder and Chief Scientific Officer, MedAbodes

▷11:00-11:20

Applications of Animal Models in I/O Drug Development

Wang Jingjing, General Manager of Taicang Company, Crown Bioscience

▷11:20-12:00

Roundtable Discussion: Global Trends and Opportunities in Immunotherapy from the AACR Perspective

Li Jia, Partner at Langsheng Investment (Moderator)

Li Dan, Deputy General Manager, Boya Fangzhou Venture Capital

Yi Lin, Partner, Defu Capital

Shi Yongling, Partner at Juming Venture Capital

Ning Gaojian, Managing Director, Yuansheng Venture Capital

▷12:00-13:30

Lunch

▷13:30-13:50

Applications of JAK1 Inhibitors in Autoimmune Diseases

Jiang Fei, Chief Investment Officer, Greater China, CMS Pharmaceutical

▷13:50-14:10

Development Progress of Bispecific Antibody Drug Projects

Wu Chenbing, CEO of Akeso Biopharma

▷14:10-14:30

Discovery of Novel Adenosine Receptor A2aR/A2bR Antagonists for Tumor Immunotherapy

Wang Yonghui, Adjunct Professor at Fudan University and Co-founder of LiDi Pharma

▷14:30-14:50

Progress in the Development of Allogeneic CAR-T Therapeutics

Yin Wenjie, Senior Director of the Pharmacology and Toxicology Department at Gracell Biotechnologies

▷14:50-15:10

Development of Immunotherapeutic Agents to Overcome Tumor Drug Resistance and Recurrence

Wang Peng, Executive Director of In Vitro R&D, Crown Bioscience

▷15:10-15:30

T Cell-Based Immunotherapy

Guest Itinerary: Being Finalized

Scan the QR code to register now

Hall C - C104, August 16

▷09:00-09:05  

Host's Opening Remarks

Chen Feng, Vice President of Colin Lican

▷09:05-09:35  

Keynote Address: 2024 Global Biopharmaceutical Licensing/M&A Trends and Strategies

Hu Qicong, Partner and Managing Director at Boston Consulting Group (BCG)

▷09:35-10:45

Roundtable Discussion: How MNCs Innovate and Collaborate with Chinese Pharmaceutical Companies for Mutual Success

Chen Feng, Vice President of Colinlicon (Moderate)

Niu Ying, Head of Search & Evaluation, Pfizer China

Wang Xin, Director of Global Expansion & Asia-Pacific Business Development at Servier

Zheng Hongshu, Senior Director of Market Access, Asia-Pacific & Senior Director of Business Development, China, at Pierre Fabre Pharmaceuticals

Xia Mingde, Founder and CEO of InnoLake Pharma

Sheng Yanci, General Manager of Global Strategy and Project Management at Henlius

▷10:45-12:00

Roundtable Discussion: Navigating the Winter—Strategic Considerations for BD and Transaction Prospects of Chinese Domestic Biotech Companies

Yang Dazhou, Vice President of Business Development at Rxilient Medical (Moderator)

Zou Lihui, CEO and Co-founder of Dage Biotech

Hu Huiguo, Director, Chief Business Development Officer, Senior Vice President, and Board Secretary of Mabwell Biosciences

Jiang Fei, Chief Investment Officer (Greater China), CMS Pharmaceutical

Yang Jianguo, CEO of Neighbor Biotech

▷12:00-14:00

Lunch

▷14:00-17:20

Innovation Project Pitch*10 (20 min/project)

Changsen Pharmaceutical, Kejun Medicine, Tuohong Kangheng, MetCure Pharmaceuticals, Weisijin Biotech, Zhuguang Biotech, Weizhen Biotech, Langrui Biotech, Keyi Pharmaceutical, Yongxin Biotech

Scan the QR code to register now

Hall C - C104 August 15

▷09:00-09:20

Development of a Novel Class of Small-Molecule Conjugates Based on Molecular Glue Payloads – Zhihua Ren, Vice President and Dean of the Institute of New Drug Research, Kintor Pharmaceutical

▷09:20-09:40

Global Trends in Small Molecule Drug Development (Targets, Disease Areas, Companies)

▷09:40-10:00 

Exploring Differentiated Pathways in the Development of GLP-1 Receptor Agonists
Chen Wei, Deputy General Manager, Gan & Lee Pharmaceuticals

▷10:00-10:20

The Trend of AI-Accelerated Chemical Synthesis
Li Liyan, Merck China, Digital Product Manager

▷10:20-10:40

The Dilemma, Challenges, and Transformation of China's Innovative Drugs
Hu Shaojing, CEO of ScanRidge

▷10:40-11:00

AI + Automation Empowering New Drug R&D
Xu Tao, Vice President, Zhihua Technology

▷11:00-11:20

Fast to First-in-Human (FIH) vs. Fast to Market -- Common CMC Challenges and Strategies
Huang Lianfeng, Chief Scientist, Crystal Pharmatech

▷11:20-11:40 

AI-Computation-Driven Development of Allosteric Small-Molecule Agonists
Shen Qiancheng, CEO of Yudao Bio

▷11:40-13:30 

Lunch

▷13:30-13:50

Development of Next-Generation BTK Inhibitors
Li Yingfu, Founder & Chairman of Chengdu HybriMed

▷13:50-14:10

Rediscovery of Paclitaxel: An innovative oral Paclitaxel softgel capsule product for improving cancer therapeutics
Huang Huiyu, Chief Scientific Officer, Meiji Biotech

▷14:10-14:30

How to Effectively Conduct Risk Assessment in Innovative Drug R&D?
Chen Hong, Distinguished Expert of the State Administration of Foreign Experts Affairs

▷14:30-14:50

Case Studies on Trace Impurity Research and a Platform for High-Difficulty Impurity Analysis
Feng Shengxi, Aiqixi, General Manager

▷14:50-15:10

Key Points in Preclinical Pharmacological Studies of Drugs for Nervous System Diseases
Jiang Wanxiang, GreenTech, Deputy General Manager

▷15:10-15:30

Pharmaceutical Considerations for Rapidly Advancing a PCC to IND
Tang Kaiyong, Vice President, Hongbo Zhiyuan

▷15:30-15:50

Risk Assessment and Control Strategy Considerations for Nitrosamine Drug-Related Impurities
Yudong Cao, LianTuo Bio, Head of CMC

▷15:50-16:10 

Development of Innovative Immunotherapies for Gastrointestinal Diseases and Gastrointestinal Tumors
Hu Pingsheng, CEO of Guizhou Shengnuo Biotechnology

Scan the QR code to register now

Hall C - C104, August 16

Forum Conference Chair: Luo Youfu, Professor, Sichuan University

Vice Chair of the Forum: Ye Tinghong, Professor, Sichuan University

Secretary-General of the Forum: Ouyang Liang, Professor, Sichuan University

Hall C - C105 August 15

Forum Planner: Zou Linglong, Founder, Chairman & CEO of Kangweixun Biology

▷09:00-09:30

Innovative TCE Technology Reduces CRS Risk and Enhances Druggability Potential
Cao Guoshuai, Tiangang Medino, Head of R&D

▷09:30-10:00

Rapid IND Filing Strategies for Antibody Drugs in China and the United States
Jiang Weidong, Founder & CEO of Kangkang Bio

▷10:00-10:30 

Key Points for Nonclinical Studies in IND Applications in China and the United States
He Quanren, Senior Vice President of Pharmacology and Toxicology, Abogen Biosciences

▷10:30-11:00

Key Points of CMC Submissions in China and the United States
Audrey Jia, Former FDA Pharmaceutical Reviewer and Founder of Data Revive

▷11:00-11:30

Strategies and Practical Insights for Bioanalysis in Dual US-China Regulatory Submissions
Zou Linglong, Founder, Chairman & CEO of Kangweixun Biology

▷11:30-13:30

Lunch

▷13:30-14:00

Immunogenicity Testing Strategy & Regulatory Expectation on Method Validation- FDA perspective
Yan Haoheng, Head of U.S. Registration at Henlius, Former FDA Reviewer

▷14:00-14:30 

Clinical Trial Design and Data Management for Overseas Regulatory Submissions
Yang Xiugao, Senior Medical Director, CSPC Pharmaceutical Group

▷14:30-15:00

ADME Research Strategies, Methods, and Case Studies Supporting the Global Expansion of ADCs
Zhu Mingshe, Ruidi Pharmaceutical, Chief Scientific Officer & Chief Advisor

▷15:00-15:30

Key Points of eCTD Submissions in China and the United States
Ren Chong, Deputy Director of Regulatory Affairs and Registration, Henlius

▷15:30-16:30

Roundtable Discussion: Dual Filing Pathways for Innovative Drugs in China and the U.S.—How to Evaluate Value Return from Multiple Dimensions?

1. Market Access Strategies for Innovative Drugs in China and the United States?

2. Impact of Market Access Pathways on Drug Value

3. What key factors should be considered when conducting clinical trials?

4. What is the impact of regulatory compliance on drug time-to-market and costs?

5. How to Identify and Manage Potential Risks?

Chen Chunlin, Founder & CEO of Medicilon

(More guest itineraries to be confirmed)

Scan the QR code to register now

Hall C - C105, August 16

▷09:30-10:00

Riding the Wind and Waves: The Current Status and Prospects of Chinese Pharmaceutical Companies Going GlobalLuo Shizhong, Founding Partner of Anjin “Medical and Health Internationalization” Innovation Cooperation Center and CEO of Anjin Biotech

▷10:00-10:30

Meeting Clinical Needs and Enhancing Treatment Accessibility: On the Development of FDA 505(b)(2) Innovative Drugs
Sun He, Global Vice President of Tasly Holding Group

▷10:30-11:00

Setting Sail: Global Expansion of Pharmaceutical Formulations to Support Long-Term Corporate Growth
An Xiaoxia, General Manager & Chairman of Shanghai Desano Pharmaceutical Group Co., Ltd.

▷11:00-11:30 

Topic TBD

▷14:00-14:30

Project Management of Overseas Clinical Trials
Wang Lina, Senior Clinical Operations Consultant at a Renowned Pharmaceutical Company

▷14:30-15:00

Practices and Reflections on Exporting Generic Drugs to the U.S. Market
Tao Yongliang, Chief Representative of the China Representative Office of Gemma Lab Co., Ltd. (USA)

▷15:00-15:30

Pharmaceutical Companies’ Global Expansion and BD Deal Structure Design: Key Legal Considerations
Liu Tingting, Senior Lawyer at AllBright Law Offices (Shanghai)

Scan the QR code to register now

Hall C - Booth C106, August 15-16

August 15

Precision Delivery – Nanopreparation Special Session

▷9:30-10:00  

Research Progress and Prospects of Nanodrug Formulations for Overcoming Drug Delivery Barriers
Lu Weiyue
Professor at Fudan University

▷10:00-10:30  

Design and Clinical Translation of Nanomedicines
Shen Youqing

Professor, Zhejiang University

▷10:30-11:00    

Innovative R&D and Clinical Filing Experience of Lipid Nanomedicines

▷11:00-11:30  

Controlled Preparation of Nanocrystals and Their In Vivo Fate
Lu Yi
Associate Professor, Fudan University

▷14:00-14:40

New Strategies and Technologies for Studying the Druggability of Nanotherapeutics

▷14:40-15:20

Development of Novel Multifunctional Tumor-Targeting Liposomes Based on Natural Compounds
Wang Jianxin
Professor, Fudan University

▷15:20-16:00

Development Practices and Reflections on Nanoemulsions
Yuan Xudong
Founder & CEO of Aikang Pharmaceutical

▷16:00-16:30

Challenges and Solutions in the Industrialization of Nanoparticle Formulations

August 16

Conquering High-End and Cutting-Edge Technologies: Special Session on Complex Injectables

▷9:30-10:00

Current Status, Opportunities, and Challenges of Long-Acting Injectables

Li Yaping

Researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences

▷10:00-10:30

Product Design and Quality Control Strategies for Complex Injectables
Zhou Jianping
Professor at China Pharmaceutical University

▷10:30-11:00 

Process Considerations for Complex Injectables from Laboratory-Scale, Pilot-Scale to Commercial Manufacturing

Xu Shanghu

Director, Chemical Research Laboratory II, Sichuan Huiyu Pharmaceutical

▷11:00-11:30

Complex Injectables: Research and Practice from Generic to Innovative

▷14:00-14:30

Innovation and Industrialization Practices for Complex Injectables

▷14:30-15:00 

Applications and Challenges of In Situ Gels in Drug Delivery
Qi Xiaole
Associate Professor, China Pharmaceutical University

▷15:00-15:30 

Impact of the PIC/S GMP Annex on Sterile Medicinal Products on Inspections of Sterile Drugs in China

Xia Luhua

Vice President, Chongqing Yuyan Pharmaceutical Co., Ltd.

Scan the QR code to register now

Hall D - D101 

Morning of August 15
Introduction — Regulatory Policies for Category B Certificate Enterprises

▷9:30-10:00  

Origins of the MAH System and Analysis of Current Trends in the Industry for Class B Licenses
Zhang Ziran, Special Vice President of the China Pharmaceutical Industry Association; Director of the Committee on Medical Policies and Regulations, China Pharmaceutical Industry Association

▷10:00-10:30  

Requirements for the Competency and Professionalism of Key Personnel in Type B Certificate-Holding Enterprises
Xie Haiyan, General Manager of the Quality Management Headquarters and Director of Formulation Quality at Livzon Pharmaceutical Group; Qualified Person (QP) for Manufacturing License B at Livzon Pharmaceutical Group; Chairperson of the Qualified Person Committee for Drug Production Quality, Guangdong Pharmaceutical Association

▷10:30-11:00    

Practical Experience Sharing from B-License Holders: How to Obtain a B License Under Current Regulations
Drug Regulatory Expert

▷11:00-11:30  

Quality System Lifecycle Management—Quality Maturity (QLM-QMM)
Bi Ruifeng, Senior GMP Expert

Morning of August 15
Production Section — Contract Manufacturing by Type B License Holders

▷14:00-14:30

Interpretation of the Latest Regulatory Policies on Entrusted Production
Shao Rong, Executive Deputy Director of NDPE at China Pharmaceutical University, and Executive Dean of the School of Drug Regulatory Science

▷14:30-14:50

Practical Experience in Full Lifecycle Management of Drugs by Marketing Authorization Holders (MAHs)
Liu Chao, Marketing Director of Shandong Benew Pharmaceutical Co., Ltd.

▷14:50-15:20

Risk Assessment and Case Sharing for Co-line Production Entrusted by B-License Holders
Tan Hongyu, Senior National GMP Inspector, Former Key Inspector of the CFDA

▷15:20-15:40

Key Points for Establishing a Quality System for Contract Manufacturing by Marketing Authorization Holders and Risk Analysis
Zhang Fayu, Beijing Kanglihua Consulting Service Co., Ltd. + Project Manager, Senior GMP Consultant

▷15:40-16:10  

How Should MAH B-License Holders Select and Audit Entrusted Manufacturing Enterprises?

Morning of August 16
Product Section — Product Initiation for B-License Holders

▷9:30-10:00

Strategic Framework and Case Studies for Product Initiation by MAH Category B License Holders

▷10:00-10:30

Pharmaceutical Process Technology Management under the MAH System
Wu Jun, Expert in Pharmaceutical Manufacturing Systems Engineering and GMP

▷10:30-11:00 

Regulatory Requirements and Common Issues for Product Technology Transfer Under the MAH System

▷11:00-11:30

Key Focus Areas and Defect Case Analysis in On-Site Inspections for Drug Registration by MAH B-License Holders
Teacher Yang, National GMP Inspector; Guest Lecturer at the Advanced Training Institute of the National Medical Products Administration

Afternoon of August 16
Change Management — Change Control for B-License Holders

▷14:00-14:30

Key Considerations for Research and Submission of Post-Approval Changes to Drugs
Mr. Yang

▷14:30-15:00 

Regulatory Requirements and Practical Guidelines for Site Changes Under the MAH System
Ma Haitao, Vice President of R&D and Technology, Guangzhou Guobiao Pharmaceutical Technology Co., Ltd.

▷15:00-15:30 

Regulatory Requirements and Practical Guidelines for Change of Marketing Authorization Holder under the MAH System

Scan the QR code to register now

Hall D - D102

Morning of August 15
A Multi-Billion Dollar Market: How Should Inhaled Preparations Be Developed?

▷9:30-10:00  

Reflections on Innovations in Inhaled Drug Delivery
You Yizhong, Chief Pharmacist and Associate Chief Physician at Changzhou No. 1 People's Hospital; Lifetime Honorary Chairman of the Aerosol Professional Committee of China Packaging Federation; Honorary Chairman of the Inhalable Particles Professional Committee of Chinese Society for Particuology

▷10:00-10:30  

Challenges and Response Strategies in the Development of Traditional Chinese Medicine Inhalation Preparations
Liao Yonghong, Researcher, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences

▷10:30-11:00    

Development Strategies and Challenges of Modified Inhaled Preparations
Wu Wenzhe, Head of the Nasal and Inhalation Drug Delivery Research Laboratory, National Engineering Research Center for Advanced Pharmaceutical Manufacturing

▷11:00-11:30  

Development Challenges and Countermeasures for Reservoir-Type Dry Powder Inhalers
Dr. Kaiqi Shi, Founder & General Manager of Suzhou Yihe Pharmaceutical Co., Ltd.

Afternoon of August 15
Riding the Wind and Waves—What Are the Challenges in BE Studies for Inhaled Formulations?

▷14:00-14:30

The Role and Prospects of Inhalation Therapy in the Treatment of Chronic Airway Diseases
Yin Kaisheng, Second-Level Professor, Chief Physician, and Doctoral Supervisor, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University; Advisor to the Asthma Group of the Respiratory Branch of the Chinese Medical Association; Co-Chairman of the China Asthma Alliance

▷14:30-15:00

Human Bioequivalence Evaluation Studies for Inhalation Products
Zheng Heng, Expert at the Center for Drug Evaluation (CDE), National Medical Products Administration; Inspection Expert, Hubei Provincial Medical Products Administration

▷15:00-15:45 

Research on Critical Quality Attributes of Orally and Nasally Inhaled Products, In Vitro Bioequivalence APSD Evaluation Methods for Generic Inhaled Drugs, and Key Updates to EMA and FDA Guidance
Shen Danlei, Chair of the China Inhalation Drug Delivery Alliance and General Manager of Nanjing Bailing Information Technology Co., Ltd.

▷15:45-16:15

Discussion on Key Quality Points in Clinical Trials of Inhalation Products
Zhou Yan, Deputy General Manager of Anhui Wanbang Pharmaceutical Technology Co., Ltd.

Morning of August 16
The Future Is Here—What Are the Industrialization Barriers for Inhalation Products?

▷9:30-10:00

High-Barrier Inhaled Drug Development: How to Gain a Competitive Advantage
Tong Zhenbo, Professor at Southeast University

▷10:00-10:30

Development and Quality Research of Nasal Sprays
Gu Li, Founder & General Manager of Nanjing Zhangyi Pharmaceutical Technology Co., Ltd.

▷10:30-11:00 

PulmoSol vs. PulmoSphere: Formulation Technologies and R&D Challenges of Dry Powder Inhalers
Liu Hengli, Head of R&D Center, Kexin Yuanda Pharmaceutical Co., Ltd.

▷11:00-11:30

Compatibility Studies and Implementation of Packaging for Inhalation Products
Cai Rong, Senior Engineer (Professor-level), Formerly at the Shanghai Institute for Testing of Food and Drug Packaging Materials

August 16, Afternoon
The Road Is Long and Arduous—How Can Inhaled Formulations Surmount the Mountain of Regulatory Approval?

▷14:00-14:30

A Brief Review of the Regulatory Assessment and Guidelines for Inhaled Products in Europe and the United States
Zhang Xingyi, Former Senior Reviewer at the CDE

▷14:30-15:00 

Key Points and Case Analysis for Regulatory Submission of Inhalation Products

▷15:00-15:30 

Regulatory Review and Evaluation of Dry Powder Inhalation Formulations in China and Europe, and Associated Technical Challenges
Chen Yongqi, Chairman and Chief Scientist of Zhuhai Respray Pharmaceutical Technology Co., Ltd.

Scan the QR code to register now

Hall D - D103 August 15-16

August 15, Morning: Insight into Policies, Clarity on the Transdermal Landscape

Host: Ma Haitao, Vice President of R&D Technology at Guangzhou Guobiao Pharmaceutical Technology Co., Ltd.

▷9:30-10:00  

Comparison of Domestic and International Regulations for Transdermal Drug Product Development: Case Studies
Quan Danyi, Chairman and Director of the Jiangsu Industrial Technology Research Institute for Novel Drug Delivery Systems

▷10:00-10:30  

Underlying Logic of Transdermal Drug Delivery Systems: Drug Selection and Development
Zhang Zhefeng, Former Senior Reviewer at the CDE and Chairman of Nanjing Zhihe Pharmaceutical

▷10:30-11:00    

Formulation Development and Characterization of Percutaneous Semi-Solid Preparations
Gu Li, Founder and General Manager of Nanjing Zhangyi Pharmaceutical Technology Co., Ltd.

▷11:00-11:30  

Application of IVPT Based on the Vertical Diffusion Cell Method in the Development of Topical Formulations
Duan Yunjian, Technical Director of Shenzhen Huarong Analytical Instruments Co., Ltd.

August 15, Afternoon
Deconstructing Technology to Overcome the Challenges of Transdermal Delivery

Host: Zhu Yadong, Technical Application Director at Suzhou Yike Xinchuang Scientific Instrument Co., Ltd.

▷14:00-14:30

Innovations for health. TTS/OTF/MAP/OBDS drug delivery solutions for improved patients’ outcome
Stefan Arnold, Director of Business Development for Asia and Head of the Asia Office at LTS Lohmann Therapie-Systeme AG

▷14:30-15:00 

Development Strategies and Case Studies for Differentiated High-End Transdermal Formulations

Wu Chuanbin, Chairman of Guangzhou Xinji Pharmaceutical Co., Ltd., Professor at Jinan University

▷15:00-15:30

Current Status and Prospects of Excipients in Transdermal Preparations
Wu Zhenghong, Professor and Doctoral Supervisor at China Pharmaceutical University

▷15:30-16:00

Case Study on the Development of Improved New Drugs via TDDS: From Project Initiation and Feasibility Analysis to Clinical Trials
Zhang Hailong, President of Changsha Jingyi Pharmaceutical Technology Co., Ltd.

▷16:00-16:30 

[Roundtable Discussion]

Morning of August 16
Iterative Technology: Mastering the Essentials of Transdermal Delivery

▷9:30-10:00

Logical Framework and Practice in the Technical Review of Transdermal Preparations
Zhang Xingyi, Former Senior Reviewer at the CDE

▷10:00-10:30

Clinical Study Design for Transdermal Products: Case Sharing
Yali Liu, Deputy Director of the Institution and Director of the Phase I Clinical Trial Ward, The First Affiliated Hospital of Shantou University Medical College

▷10:30-11:00 

Key Points in the Experimental Design, Implementation, and Bioanalysis of Clinical Trials for Transdermal Drug Delivery Systems
Jiang Hongliang, Chairman of Wuhan Hongren Biopharmaceutical Co., Ltd.

▷11:00-11:30

Applications and Challenges of Dissolving Microneedle Technology in the Pharmaceutical Field
Li Chengguo, Co-founder of U-Well (Zhuhai) Biotechnology Co., Ltd.

Afternoon of August 16
Reference Cases: A Comprehensive Guide to Transdermal Delivery

▷14:00-14:30

Case Study of Adapalene Gel Patch: Barriers to Product Initiation and Development

▷14:30-15:00 

Case Study of Flurbiprofen Cataplasm: Barriers to Product Initiation and Development

▷15:00-15:30 

Taking Tacrolimus Ointment as an Example: Barriers to Product Initiation and Development

Scan the QR code to register now

Hall D - D104

August 15

▷9:30-10:00  

Generic Drug Companies’ Strategic Restructuring: From a Big-Product Strategy to a Major Brand Campaign!

▷10:00-10:30  

Tapping into the “Blue Ocean” of the Big Health Industry: How Can Pharmaceutical Companies Optimize Their Strategic Layout?

▷10:30-12:00  

Dialogue with Decision-Makers | Clash of Core Insights from 30 Entrepreneurs and Executives

Dialogue with Decision-Makers | Hone Internal Strengths, Await the Right Moment

Dialogue with Decision-Makers | Sifting Through the Sands: The Genesis Era of Domestic Generic Drug Brands

Dialogue with Decision-Makers | Surviving Hypercompetition: The Last One Standing Wins

Dialogue with Decision-Makers | Precision Focus, Marketing Empowerment

Dialogue with Decision-Makers | The Harsh Winter Has Passed, Dawn Has Arrived

Dialogue with Decision-Makers | The Era of Value-Based Healthcare Has Arrived; Only Innovation Can Secure the Future

Dialogue with Decision-Makers | Leveraging Core Competencies in Key Domains

........ 

▷14:00-14:30

Top 10 Current Trends in the Generic Drug Industry in 2024

▷14:30-15:00

Future-Oriented Generic Drug Project Initiation: How to “Begin with the End in Mind”?

▷15:00-16:30 

Dialogue with Decision-Makers | Clash of Core Perspectives from 20 Entrepreneurs and Executives

Dialogue with Decision-Makers | Dosage Form and Product Differentiation Are the Way Forward for Solutions in Specialty Indications

Dialogue with Decision-Makers | Seeking Opportunities in Crisis

Dialogue with Decision-Makers | Making Innovation Sustainable

Scan the QR code to register now

Hall D - D105

August 15

▷9:30-10:00  

Inheriting and Innovating: Traditional Chinese Medicine Leads the Future of Health
Cheng Jianming, Professor at the School of Pharmacy, Nanjing University of Chinese Medicine; Director of the Jiangsu Provincial Engineering Center for Classical Prescriptions

▷10:10-10:50

Four-Pronged Approach to Cultivate New Quality Productive Forces and Drive High-Quality Development of the Traditional Chinese Medicine Industry
Zhang Tiejun, Chief Expert in Traditional Chinese Medicine, Tianjin Institute of Pharmaceutical Research Co., Ltd.

▷10:50-11:30

Discussion on Policies, Regulations, and Supervision of Traditional Chinese Medicine Formula Granules

▷11:30-12:10

Strategies for the Transformation of Hospital-Prepared Formulations into Innovative Traditional Chinese Medicines
Bo Dong, Director of the Research Center for Chinese Medicine Formulas and Syndromes, Institute of Basic Theory of Chinese Medicine, China Academy of Chinese Medical Sciences; Researcher; Doctoral Supervisor

▷14:00-14:40 

Innovative Traditional Chinese Medicine Drug Development from the Perspective of Traditional Chinese Medicine Theory
Zhang Guangji, Deputy Secretary of the Party Committee and Second-Grade Professor at Zhejiang Chinese Medical University; from a family with a long tradition of practicing Traditional Chinese Medicine

▷14:40-15:20

From Modern Chinese Medicine to Digital-Intelligent Chinese Medicine: Tasly’s Innovative Practices and Reflections in TCM R&D
Zhou Shuiping, Executive Dean of Tianjin Tasly Research Institute

▷15:20-16:00

New Drug Development Based on the Salvia miltiorrhiza and Notoginseng Herb Pair
Jiang Baohong, Researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences

▷16:00-16:40 

Discovery of Novel Targets Based on Active Ingredients of Traditional Chinese Medicine
Kou Junping, Professor at China Pharmaceutical University

August 16

▷9:30-10:10

Discussion on R&D Strategies for Innovative Traditional Chinese Medicine Formulations
Chen Daquan, Professor at Yantai University

▷10:10-10:50

Analysis of Issues Related to Clinical Trials for Drugs with the Same Name and Formula
Gao Rui, Chief Researcher at the China Academy of Chinese Medical Sciences, and Deputy Director of the Institute of Clinical Pharmacology, China Academy of Chinese Medical Sciences

▷10:50-11:30

Discussion on Differentiated Product Selection Strategies for Enterprise New Product Development Based on Human Use Experience
Shang Qiang, Executive Vice Dean of the Institute of Traditional Chinese Medicine, Livzon Pharmaceutical Group

▷11:30-12:10

Evidence-Based Medical Research for the R&D and Clinical Application of Modern Traditional Chinese Medicine: Exploration and Practice

▷14:00-14:30

Clinical Studies on New Traditional Chinese Medicine Drugs under the “Three-in-One” Evidence Review System
Fan Minwei, Deputy Director of the National Engineering Research Center for Traditional Chinese Medicine Pharmaceutical Technology

▷14:30-15:00 

Key Technical Issues and Solutions in the Research and Development of Classical Formulas

▷15:00-15:30 

Research Progress on Continuous Manufacturing of Traditional Chinese Medicine Preparations—PAT and Mathematical Modeling Technologies
Du Ruofei, Associate Research Fellow, Shanghai University of Traditional Chinese Medicine

Scan the QR code to register now

Hall D - D106

August 15

▷9:30-10:00  

Development Strategies and Case Studies for Modified New Drugs
Zhang Ning, Professor at Xi’an Jiaotong-Liverpool University, Former Senior Reviewer at the Center for Drug Evaluation (CDE)

▷10:00-10:30  

Targeted Drug Delivery to Hair Follicles and New Drug Development
Sheng Xiaoxia, General Manager of Hangzhou Lingye Pharmaceutical Technology Co., Ltd.

▷10:30-11:00    

Key Technologies and Case Studies in the Development of Improved New Drugs Based on Complex Injectables
He Zhonggui, Chief Scientist of Shenyang Xinda Taikang Pharmaceutical Technology Co., Ltd.

▷11:00-11:30  

Case Studies on the Project Initiation and R&D of Improved Oral Dissolving Films
Xu Jianming, Dean of Zhejiang Heze Pharmaceutical Research Institute

▷14:00-14:40

“Establish,” “Revise,” and “Improve”: Three Key Steps for the Market Launch of Improved New Drugs
Yang Jin, Professor at China Pharmaceutical University

▷14:40-15:20

Development and Reflections on Combination Drug-Device Products
Luan Hansen, CTO of Heyan (Shanghai) Medical Device Co., Ltd.

▷15:20-16:00

Reflections on the Manufacturing Process and Industrialization of Sustained- and Controlled-Release Microspheres
You Jian, Professor at Zhejiang University

▷16:00-16:40

Case Sharing on the R&D of Improved New Drugs for Children

Qi Yiguang, General Manager, Beimei R&D (Shenzhen) Co., Ltd.

August 16

▷9:30-10:00

Case Study on the Improvement of Transdermal Preparations: Correlation Experiments and Design for Key Quality Attributes (CQAs)

Wang Qing, Professor at Dalian University of Technology

▷10:00-10:30

Strategies for the Improvement and Innovative Development of Film Formulations
Chen Fang, Researcher at the National Engineering Research Center for Advanced Pharmaceutical Manufacturing

▷10:30-11:00 

Case Analysis of the Difficulties in R&D and Industrialization of Improved New Drugs

Wu Siqing, Founder & Chairman of Hunan Jiuwei Biopharmaceutical Co., Ltd.

▷11:00-11:30

Key Technologies and Case Studies for Oral Formulations of Poorly Soluble Drugs
Wang Zeren, Co-founder, Chairman, and Chief Scientist of Shenzhen Yaoxin Biotech

▷14:00-14:30

Case Study on the R&D of Nanomedicine Drug Delivery Systems: A Focus on Alzheimer’s Disease
Gao Huile, Professor at Sichuan University

▷14:30-15:00 

Case Studies and Reflections on the Development of Ophthalmic Preparations: A Focus on Dry Eye Disease
Zhang Yu, Professor at Shenyang Pharmaceutical University

▷15:00-15:30 

Applications and Case Studies of Lyophilization Technology in Complex Formulations

Liu Hengli, Head of the R&D Center at Kaixin Yuanda Pharmaceutical Co., Ltd.

Scan the QR code to register now

Hall D - D107

August 15

▷9:30-10:10  

From Imitation to Improvement: Unearthing Opportunities in Niche Segments
Wang Lifeng, Founder of Huiyao Consulting

▷10:10-10:50  

Project Initiation and Clinical Development Strategy for Improved Modified-Release Formulations
Xia Yan, Rotating General Manager of Baihuacun Pharmaceutical Group and Chairman of Lihua Bio

▷10:50-11:30    

Strategies and Implementation Cases for the Initiation of Improved New Drugs Based on Clinical Needs
Wu Tao, Chief Scientist at Beijing Huicheng Ruixiang Pharmaceutical Biotechnology Co., Ltd.

▷11:30-12:10  

Insights for the Initiation of Improved New Drug Projects from Successfully Launched 505(b)(2) Cases
Chen Hong, Distinguished Expert of the State Administration of Foreign Experts Affairs

▷14:00-14:40

Product Initiation and Case Sharing Guided by the Transdermal Drug Delivery Technology Platform
Sun Yazhou, Co-founder, Director, Senior Engineer of Changsha Jingyi Pharmaceutical Technology Co., Ltd.; Distinguished Lecturer at the NMPA Advanced Training Institute

▷14:40-15:20

Product Initiation and Case Studies Guided by the Osmotic Pump Technology Platform
Shi Jinmin, Deputy General Manager of Handu Pharmaceutical

▷15:20-16:00

Product Initiation and Case Studies Guided by Ocular Drug Delivery Technology Platform
Wei Jiye, Chairman of Suzhou Weiyoo Gene Biotechnology Co., Ltd.

▷16:00-16:40

Product Initiation and Case Sharing Guided by the Pediatric Drug Taste-Masking Technology Platform

August 16

▷9:30-10:20

Unique — Product Selection Strategy Based on Distinctive and Differentiated Layout

Guo Xinfeng, Founder of Nanjing Evidence-Based Biotechnology Co., Ltd.

▷10:20-11:30

Cost Advantage—Selection Strategy for Volume-Based Procurement Items
Zhang Tingjie, Founder of Fengyun Yaotan

▷11:30-12:10 

Technological Leadership: Project Initiation and Success Stories of Improved New Drugs with High Technical Barriers

Wei Shifeng, Chairman and CEO of Beijing Luonuoqiangshi Pharmaceutical Technology R&D Center Co., Ltd.

▷13:30-14:30

Product Is King—Generic Drug Project Initiation Strategies and Product Portfolio in an Era of Intense Competition

Wei Lijun, Founder and CEO of Beijing Yaoyan Information Consulting Co., Ltd.

▷14:30-15:00 

In Full Swing—Precise and Decisive Project Initiation in the Traditional Chinese Medicine Sector

Wang Hailin, Sales Director at Nanjing Hengdao Pharmaceutical, Founder of Drug Screening, Researcher on Data and Policies in the Pharmaceutical Industry, and Explorer of Pharmaceutical Marketing

Scan the QR code to register now

Hall E - E105 August 15

Agenda Updating, Stay Tuned...

Scan the QR code to register now

Hall E - E105 August 16

▷09:00-09:30

Exploration of Vertical Industry Chain Collaboration Between Active Pharmaceutical Ingredients (APIs) and Drug Formulations

▷09:30-10:00    

Annual Perspective Analysis of CMC for Active Pharmaceutical Ingredients

▷10:00-10:30  

Outlook on the Future Development of Raw Material Enterprises

▷10:30-11:00  

How to Revitalize the API Industry Amid the Pharmaceutical Winter

▷14:00-14:30    

Development Strategies for Specialty Active Pharmaceutical Ingredients

▷14:30-15:00  

Under the New Landscape, API Companies’ “New Growth Drivers”

▷15:00-15:30  

International Trade Landscape and Outlook for Active Pharmaceutical Ingredients (APIs)

▷15:30-16:00    

Strategic Layout for Niche Active Pharmaceutical Ingredients

Scan the QR code to register now

Hall E - E102, August 15

▷09:30-10:00

Liaise with domestic and overseas procurement heads

▷10:00-10:30  

Integration of API Intermediates with Synthetic Biology and Continuous Flow

▷10:30-11:00  

Strategic Cooperation Between API Manufacturers and Downstream MAHs Holding B Licenses

▷11:00-11:30  

R&D and Manufacturing Enterprise Resource Alignment, Implementation of Strategic Project Cooperation

▷14:00-14:30    

How R&D Companies Can Partner with Listed Firms for Capitalized Exit

▷14:30-14:50  

Pharmaceutical Companies Seek API Partnerships and Collaborate with API CROs

▷14:50-15:10  

Forecast of the Future Business Landscape for Domestic API CDMOs, with On-Site Networking for Partnership Opportunities

▷15:10-15:30    

Cross-Industry Reinvention, No Rat Race

Scan the QR Code to Register Now

Hall E - E103, August 15-16

August 15
Green Pharmaceutical Technology Conference: Catalysts

▷09:30-10:00    

Green Pharmaceutical Concepts and Industrial Development

▷10:00-10:30  

Practical Applications and Case Studies of Asymmetric Catalysis

▷10:30-11:00  

How Oxidation Reactions and Catalytic Oxidation Achieve Cost Reduction and Efficiency Improvement

▷11:00-11:30  

Challenges and Opportunities in Green Pharmaceutical Manufacturing

▷14:00-14:30    

Applications of Catalytic Technology in Energy Conversion and Environmental Protection

▷14:30-14:50  

Modeling, Design, and Optimization of Catalytic Reaction Engineering

▷14:50-15:10  

Regulation of Catalyst Activity and Selectivity

▷15:10-15:30    

Differentiated Development Practices in Continuous Flow Based on Process Technology

▷15:30-16:00  

Application of Continuous Reaction Technology in the Commercial Production of Small-Molecule Active Pharmaceutical Ingredients

▷16:00-16:30    

Green Catalysis Technology and Its Industrial Applications

August 15
Green Pharmaceutical Technology Conference: Continuous Flow

▷09:30-10:00    

Continuous Flow Differentiated Development Strategy

▷10:00-10:30  

Continuous Flow Retrofitting of Small-Molecule Synthesis

▷10:30-11:00  

Future Development and Transformation Trends in Continuous Flow Manufacturing Technology

▷11:00-11:30  

Case Studies on Continuous Flow Retrofitting for Small Molecule Synthesis

▷14:00-14:30    

How to Integrate Green Chemistry Principles with Continuous Flow Manufacturing Technology for Sustainable Pharmaceutical Production

▷14:30-14:50  

Case Studies on the Conversion of Reaction Intermediates and the Design of Continuous Flow Systems

▷14:50-15:10  

Application of Green Analytical Techniques in Continuous Flow Manufacturing

▷15:10-15:30    

How to Retrofit and Upgrade Hardware for the Scale-Up Production of Continuous-Flow Microchemical Processes

▷15:30-16:00  

Challenges and Bottlenecks in Continuous Manufacturing Equipment for the Pharmaceutical Industry

▷16:00-16:30    

The Essence and Implementation Pathways of Green Chemistry

Scan the QR code to register now

Hall E - E101 August 15-16

August 15

▷9:30-10:00  

Development Trends and Strategic Countermeasures for Modified-Release Preparations in China

▷10:00-10:30  

Development of Oral Sustained- and Controlled-Release Preparations Based on Clinical Needs
Gao Shen, Chief Pharmacist, Shanghai Changhai Hospital

▷10:30-11:00    

Twin-Screw Hot-Melt Extrusion and Continuous Granulation from a Continuous Manufacturing Perspective
Yang Gaopin, General Manager of Suzhou Pupeishan Technology Co., Ltd.

▷11:00-11:30  

Analysis of Key Challenges in the Development of Sustained- and Controlled-Release Formulations with Case Studies
Shi Bin, CTO of Zezheng Pharma

▷14:00-14:20

Key Technical Points for Compound Oral Solid Dosage Forms
Li Mingli, Professor at Jining University, Founder of Shandong Nuomingkang Pharmaceutical Research Institute Co., Ltd.

▷14:20-14:50

Fundamental Applied Research on the Design and Development of Solid Dispersions
Cai Ting, China Pharmaceutical University

▷14:50-15:10

Research and Application of Technological Innovations in Granulation and Coating
Han Yinglong, Technical Manager of the Solid Dosage Form Division, Yichun Wanshen Intelligent Equipment Co., Ltd.

▷15:10-15:40

Technical Feasibility Assessment and Selection of Formulation and Process for Sustained- and Controlled-Release Preparations

▷15:10-15:40

Innovative Excipients for Full-Formulation of Sustained-Release Oral Solid Dosage Forms
Yang Jirong, Drug Delivery Formulation Technology Manager, Colorcon China

August 16

▷9:30-10:00

Oral Sustained- and Controlled-Release Formulations: From Theory to Practice
Fu Qiang, Professor at Shenyang Pharmaceutical University

▷10:00-10:30

Case Study on Ensuring Quality and Managing Costs in Generic Drugs—Quality and Cost Stem from Design
Lei Jifeng, Chairman of Shanghai Ambit Pharmaceuticals Technology Co., Ltd.

▷10:30-11:00 

Discussion on the Key Points and Strategies for the Consistency Evaluation of Oral Sustained- and Controlled-Release Preparations
Liang Chaofeng, Deputy Director of the Pharmaceutical Excipients Professional Committee of the Guangdong Pharmaceutical Association, Chief Pharmacist

▷11:00-11:30

Key Technologies and Case Studies of Hydrophilic Gel Matrix Tablets for Sustained Release

Scan the QR code to register now

Hall E - E102 August 16

▷09:30-10:10

Technical Considerations for Studies on Changes in Pharmaceutical Excipients After Drug Approval Liu Yanming, Deputy Director of Hunan Provincial Institute for Food and Drug Control

▷10:10-10:50  

Key Excipients and Quality Control Strategies for Nanopreparations
Sun Chunmeng, Professor at China Pharmaceutical University

▷10:50-11:30    

Registration of Pharmaceutical Excipients and Associated Review and Approval
Li Yinbo, Co-founder of Xizi Pharma

▷11:30-11:50   

Research and Application of High-Barrier Film Coating Premixes
Yang Xuecheng, Deputy General Manager, Shanghai New Phil Biopharmaceutical Engineering Technology Co., Ltd.

▷14:00-14:40

Research Progress on the Quality of Pharmaceutical Excipient Lactose and Its Application Prospects
Yuan Yaozuo, Director of the Laboratory Technology Research Division, Jiangsu Institute for Food and Drug Control

▷14:40-15:20

Application of Key Pharmaceutical Excipients in Oral Solid Dosage Forms: A Case Study
Chen Ying, Head of the Excipients Laboratory, Guangdong Provincial Institute for Drug Control

▷15:20-16:00

Risk-Based Quality Control of Pharmaceutical Excipients and Regulatory Interpretation
Mr. Xu, Head of Quality at a Renowned Pharmaceutical Company

Scan the QR code to register now

Hall E - E106 August 15-16

Morning of August 15
Omni-channel Marketing in the Pharmaceutical Industry

▷9:30-10:00  

Analysis of Development Trends in China’s Pharmaceutical Market in the Post-MAH Era

▷10:00-10:30  

In-Hospital Promotion Strategies for Prescription Drugs Amidst Centralized Procurement and Anti-Corruption Measures

▷10:30-11:00    

Online-Offline Integration: A Major Transformation in China’s Pharmaceutical Retail Sector

▷11:00-11:30  

A Comprehensive Analysis: A Holistic View of the Out-of-Hospital Market

Afternoon of August 15
Commercialization and Market Implementation Strategies for Pharmaceutical Products

▷13:00-13:30

Pharmaceutical Academic System Development and Compliant Promotion

▷13:30-14:00

The Battle of Models: Winning the Third-Terminal Market

▷14:00-14:30

The Intensive Promotion of Branded Drugs: The White Dragon Horse Path

▷14:30-15:00

The Dual Pathways of Compliance and Digitalization: How to Rapidly Build a Team

▷15:00-15:30

How Can Professional Regional CSOs Help Products Achieve Rapid Growth?

Morning of August 16
Commercialization and Market Entry Strategies for Pharmaceutical Products

▷9:00-09:30

How Can Professional Regional CSOs Help Products Achieve Rapid Growth?

▷09:30-10:00

Practical Applications of Digital Promotion in the Marketing of Innovative Drugs

▷10:00-10:30 

How Can Companies Cultivate and Develop a Team of “Medical Science Liaisons” Under the Agency Model?

▷10:30-11:00

Expert Discussion: Will Innovative Drugs Be the Next Big Trend?

Afternoon of August 16
Approval Document Trading Conference

Scan the QR code to register now